


## Cinchonine

<b>Cat. No.:</b>	HY-Y0152
<b>CAS No.:</b>	118-10-5
<b>Molecular Formula:</b>	C <sub>19</sub> H <sub>22</sub> N <sub>2</sub> O
<b>Molecular Weight:</b>	294.39
<b>Target:</b>	Apoptosis; Parasite; Autophagy; Caspase; Calcium Channel
<b>Pathway:</b>	Apoptosis; Anti-infection; Autophagy; Membrane Transporter/Ion Channel; Neuronal Signaling
<b>Storage:</b>	4°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 4.76 mg/mL (16.17 mM; Need ultrasonic)

Solvent	Mass	Concentration		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.3969 mL	16.9843 mL	33.9685 mL
	5 mM	0.6794 mL	3.3969 mL	6.7937 mL
	10 mM	0.3397 mL	1.6984 mL	3.3969 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Cinchonine is a natural compound present in Cinchona bark with antimalarial, antitumor, anti-inflammatory, anti platelet-aggregation and anti-obesity properties. Cinchonine inhibits cells proliferation and autophagy and induces apoptosis through activation of Caspase-3. Cinchonine activates endoplasmic reticulum stress-induced apoptosis in human liver cancer cells<sup>[1]</sup>.

#### In Vitro

Cinchonine induces apoptosis and inhibits cell proliferations in HepG2 and SMCC7721 (180 μM, 24 h), as well as in cells HeLa and A549 (180 μM, 48-96 h) <sup>[2][3]</sup>.  
 Cinchonine (50-100 μM, 24 h) inhibits tumor growth in lung cancer cells A549 and H1975, with IC<sub>50</sub> values of 76.67 and 87.44 μM, respectively<sup>[4]</sup>.  
 Cinchonine (0-20 μM, 24 h) blocks autophagy flux through the inhibition of a maturation of lysosomal hydrolases<sup>[4]</sup>.  
 Cinchonine (20 μM) induces osteoclast differentiation and osteogenesis<sup>[6]</sup>.  
 Cinchonine inhibits platelet aggregation through inhibition of Ca<sup>2+</sup> flux (IC<sub>50</sub>: 300 μM) and protein kinase C (IC<sub>50</sub>: 20 μM)<sup>[7]</sup>.  
 Cinchonine inhibits proliferation (0-100 μM, 72 h) of T. evansi, with IC<sub>50</sub> of 16.96 μM in 24 h <sup>[8]</sup>.  
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.  
 Western Blot Analysis<sup>[2][3][4]</sup>

Cell Line:	HeLa, A549, HepG2, SMCC7721, H1975
Concentration:	180 µM (HeLa, A549, HepG2, SMCC7721), 200 µM (A549 and H1975)
Incubation Time:	24 h-96 h (HeLa and A549), 48 h (HepG2 and SMCC7721), 24 h (A549 and H1975)
Result:	Inhibited cell proliferation in cells HeLa, A549, HepG2 and SMCC7721. Cinchonine inhibited phosphorylation of AKT and TAK1. Cinchonine activated Casapase-3, promoted GRP78 and phosphorylation of PERK and sIF2- $\alpha$ . Cinchonine reduced mature cathepsin levels and increased immature cathepsin levels.

<b>In Vivo</b>	Cinchonine (0.265-0.530 mg/kg, intratumorally injection, LLC cells for 14 days) induces cell apoptosis, suppresses tumor growth in BALB/c nude mice <sup>[2]</sup> .	
	Cinchonine exhibits anti-metastatic activity in lung cancer cells with low toxicity <sup>[4]</sup> .	
	Cinchonine(50mg/kg, i.p.) exhibits antiobesity activity in C57BL/6B mice <sup>[5]</sup> .	
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	BALB/c nude mice <sup>[4]</sup>
	Dosage:	4 mg/kg/day
	Administration:	Intraperitoneal injection, for 19 days
	Result:	Inhibited metastatic activity
	Animal Model:	BALB/c nude mice <sup>[2]</sup>
	Dosage:	0.265 and 0.530 mg/kg
	Administration:	Intratumorally injection, for 14 days
	Result:	Inhibited tumor growth with more TUNEL positive cells (DNA fragmentation indicator).
	Animal Model:	High-fat-diet (HFD) induced obesity in C57BL/6B mice <sup>[5]</sup>
Dosage:	50 mg/kg	
Administration:	Intraperitoneal injection	
Result:	Reduced body weight gain (-38%), visceral fat-pad weights (-26%).	

## CUSTOMER VALIDATION

- Biomed Pharmacother. 2023 Jun 8;164:114980.
- Front Cell Infect Microbiol. 14 June 2022.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- 
- [1]. Qi Y, et al., Cinchonine induces apoptosis of HeLa and A549 cells through targeting TRAF6. *J Exp Clin Cancer Res.* 2017 Feb 23;36(1):35.
- [2]. Jin ZL, et al., Cinchonine activates endoplasmic reticulum stress-induced apoptosis in human liver cancer cells. *Exp Ther Med.* 2018 Jun;15(6):5046-5050.
- [3]. Wang H, et al., Cinchonine exerts anti-tumor and immunotherapy sensitizing effects in lung cancer by impairing autophagic-lysosomal degradation. *Biomed Pharmacother.* 2023 Aug;164:114980.
- [4]. Jung SA, et al., Cinchonine Prevents High-Fat-Diet-Induced Obesity through Downregulation of Adipogenesis and Adipose Inflammation. *PPAR Res.* 2012;2012:541204.
- [5]. Jo YJ, et al., Cinchonine inhibits osteoclast differentiation by regulating TAK1 and AKT, and promotes osteogenesis. *J Cell Physiol.* 2021 Mar;236(3):1854-1865.
- [6]. Shah BH, et al., The inhibitory effect of cinchonine on human platelet aggregation due to blockade of calcium influx. *Biochem Pharmacol.* 1998 Oct 15;56(8):955-60.
- [7]. Rani R, et al., Intracellular ROS production and apoptotic effect of quinoline and isoquinoline alkaloids on the growth of *Trypanosoma evansi*. *Acta Trop.* 2023 Sep;245:106980.
- [8]. Jin ZL, et al. Cinchonine activates endoplasmic reticulum stress-induced apoptosis in human liver cancer cells. *Exp Ther Med.* 2018 Jun;15(6):5046-5050.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA